(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

This was the stock's third consecutive day of losses.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...